Insider Transaction Report for Tessari Eben

This filing details insider transactions by Tessari Eben, Chief Strategy Officer at Kiniksa Pharmaceuticals International, plc. On April 7, 2026, Mr. Eben acquired 2,726 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs). The RSUs, which represent a contingent right to receive Class A Ordinary Shares, vest over a four-year period. Following this acquisition, Mr. Eben disposed of 846 Class A Ordinary Shares at a price of $48.94 per share. Post-transaction, his holdings include 23,130 Class A Ordinary Shares. The RSU vesting is subject to specific conditions outlined in the footnotes of the filing.